Tasoujlu Mina, Sharifi Yaeghob, Ghahremani Maryam, Alizadeh Kasra, Babaie Farhad, Hosseiniazar Mohammadreza Mohammad
Cellular and Molecular Research Center, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Department of Microbiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Mol Biol Rep. 2025 Jan 21;52(1):143. doi: 10.1007/s11033-025-10254-3.
Inflammatory Bowel Disease (IBD) is a persistent ailment that impacts many individuals worldwide. The interaction between the immune system and gut microbiome is thought to influence IBD development. This study aimed to assess some microbiota in IBD patients compared to healthy individuals. The investigation involved a selected group of twenty patients suffering from IBD and an equal number of healthy participants. Stool specimens were obtained and analyzed for Lactobacillus, Bifidobacterium, Bacteroides, Clostridium leptum, Akkermansia muciniphila, Fusobacterium and Enterobacteriaceae using real-time PCR. The findings indicated significantly higher levels of Bifidobacterium in IBD patients (Pv = 0.009) and lower levels of A. muciniphila (Pv = 0.003) healthy individuals. Other bacteria tested did not show significant differences. The study suggests that the progression of IBD patients could be influenced by the rising of Bifidobacterium and the declining of A. muciniphila. Targeting these bacteria could lead to improved treatments and quality of life for those with IBD.
炎症性肠病(IBD)是一种影响全球许多人的持续性疾病。免疫系统与肠道微生物群之间的相互作用被认为会影响IBD的发展。本研究旨在评估IBD患者与健康个体相比的一些微生物群。调查涉及一组选定的20名IBD患者和同等数量的健康参与者。采集粪便样本,使用实时PCR分析其中的乳酸杆菌、双歧杆菌、拟杆菌、纤细梭菌、嗜黏蛋白阿克曼氏菌、梭杆菌和肠杆菌科。结果表明,IBD患者中双歧杆菌水平显著更高(Pv = 0.009),而健康个体中嗜黏蛋白阿克曼氏菌水平更低(Pv = 0.003)。其他检测的细菌没有显示出显著差异。该研究表明,双歧杆菌的增加和嗜黏蛋白阿克曼氏菌的减少可能会影响IBD患者的病情进展。针对这些细菌可能会改善IBD患者的治疗效果和生活质量。